(Q40714688)

23 September 2017

title

Ribonucleotide reductase and thymidine phosphorylation: two potential targets of azodicarbonamide (English)

1 reference

23 September 2017

Christine Fagny

1

1 reference

23 September 2017

Michel Vandevelde

series ordinal

2

1 reference

23 September 2017

Michal Svoboda

series ordinal

3

1 reference

23 September 2017

Patrick Robberecht

series ordinal

4

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

23 September 2017

published in

Biochemical Pharmacology

1 reference

23 September 2017

volume

64

1 reference

23 September 2017

issue

3

1 reference

23 September 2017

page(s)

451-456

1 reference

ADA, a potential anti-HIV drug

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

Azodicarbonamide inhibits T-cell responses in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

Azodicarbonamide as a new T cell immunosuppressant: synergy with cyclosporin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

Enzymatic assay for quantification of deoxynucleoside triphosphates in human cells exposed to antiretroviral 2',3'-dideoxynucleosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

T-lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation. Impaired pyrimidine responses are already evident at early stages of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

A model for the role of multiple cysteine residues involved in ribonucleotide reduction: amazing and still confusing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

Properties of mitochondrial thymidine kinases of parental and enzyme-deficient HeLa cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

2'-O-Acyl/alkyl-substituted arabinosyl nucleosides as inhibitors of human mitochondrial thymidine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901185-1

10.1016/S0006-2952(02)01185-1

7 January 2021

Identifiers

DOI

1 reference

23 September 2017

1 reference